$24.32-1.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Just reported
From Veracyte, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$151.8M
+15% y/y
+1.0% q/q
Guided
—
No guide given
Actual
$0.38
+58% y/y
+23% q/q
Guided
—
No guide given
EPS, adjusted: $0.51
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $151.8M | $131.9M | +15.08% |
| Profit | $31.5M | $19.1M | +64.62% |
| Profit per share | $0.38 | $0.24 | +58.33% |
| Free Cash Flow | $37.9M | $42M | -9.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Veracyte, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We delivered solid third quarter results supported by strong profitability and cash generation,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development . The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test , Decipher® Bladder Genomic Classifier test , Decipher® Prostate Genomic Classifier test , Prosigna® Breast Risk of Recurrence test , and the TrueMRD™ Monitoring Test for MIBC .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Veracyte, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$16.6M
-28% y/y
-28% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.